LncRNA expression and implication in osteosarcoma: a systematic review and meta-analysis
- PMID: 29184421
- PMCID: PMC5687481
- DOI: 10.2147/OTT.S149889
LncRNA expression and implication in osteosarcoma: a systematic review and meta-analysis
Abstract
Purpose: Osteosarcoma is the most prevalent primary bone tumor in children, adolescents, and older adults, typically presenting with poor survival outcomes. In recent years, ample evidence has shown that many long noncoding RNAs (lncRNAs) have been aberrantly expressed in osteosarcoma, demonstrating their potential to serve as prognostic markers. In this study, we performed a meta-analysis on four lncRNAs (TUG1, UCA1, BCAR4, and HULC) to systematically evaluate their prognostic value in osteosarcoma.
Materials and methods: The eligible articles were systematically searched in PubMed, Web of Science, Embase, and Elsevier ScienceDirect (up to September 22, 2017), and one meta-analysis concerning the association between lncRNA expression and the overall survival (OS) of osteosarcoma patients was performed. Survival outcomes were analyzed by OS. Subgroup analyses were performed.
Results: A total of 1,361 patients with osteosarcoma and 12 lncRNAs from 16 articles were included in the study. Of the listed lncRNAs, the high expression of 10 lncRNAs indicated worse survival outcomes, while only two lncRNAs were shown to positively affect patients' OS.
Conclusion: This meta-analysis indicated that the abnormally expressed lncRNAs might significantly affect the survival of osteosarcoma patients. Combined use of these lncRNAs may serve as potential novel biomarkers for the indication of clinical outcomes of osteosarcoma patients as well as the selection of adjuvant chemotherapy strategies for clinical treatment of this disease.
Keywords: lncRNAs; meta-analysis; osteosarcoma; prognosis.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures





Similar articles
-
The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.BMC Cancer. 2021 Feb 27;21(1):202. doi: 10.1186/s12885-021-07882-w. BMC Cancer. 2021. PMID: 33639865 Free PMC article.
-
Abnormally expressed long non-coding RNAs in prognosis of Osteosarcoma: A systematic review and meta-analysis.J Bone Oncol. 2018 Sep 22;13:76-90. doi: 10.1016/j.jbo.2018.09.005. eCollection 2018 Nov. J Bone Oncol. 2018. PMID: 30591861 Free PMC article.
-
TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: A PRISMA-compliant meta-analysis.Medicine (Baltimore). 2017 Nov;96(46):e8583. doi: 10.1097/MD.0000000000008583. Medicine (Baltimore). 2017. PMID: 29145271 Free PMC article.
-
Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.Cell Physiol Biochem. 2017;42(4):1407-1419. doi: 10.1159/000479205. Epub 2017 Jul 17. Cell Physiol Biochem. 2017. PMID: 28715796 Review.
-
Long noncoding RNAs as potential biomarkers and therapeutic targets in gallbladder cancer: a systematic review and meta-analysis.Cancer Cell Int. 2019 Jun 28;19:169. doi: 10.1186/s12935-019-0891-1. eCollection 2019. Cancer Cell Int. 2019. PMID: 31297033 Free PMC article. Review.
Cited by
-
Prognostic role of long non-coding RNA HNF1A-AS1 in Chinese cancer patients: a meta-analysis.Onco Targets Ther. 2018 Aug 31;11:5325-5332. doi: 10.2147/OTT.S163575. eCollection 2018. Onco Targets Ther. 2018. PMID: 30214238 Free PMC article.
-
LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis.Mol Med. 2020 Mar 18;26(1):26. doi: 10.1186/s10020-020-00155-5. Mol Med. 2020. PMID: 32188407 Free PMC article.
-
LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340-5p and PI3K/AKT pathway.Aging (Albany NY). 2021 May 28;13(16):20116-20130. doi: 10.18632/aging.203047. Epub 2021 May 28. Aging (Albany NY). 2021. PMID: 34048366 Free PMC article.
-
LncRNA BDNF-AS is associated with the malignant status and regulates cell proliferation and apoptosis in osteosarcoma.Biosci Rep. 2018 Nov 15;38(6):BSR20181498. doi: 10.1042/BSR20181498. Print 2018 Dec 21. Biosci Rep. 2018. PMID: 30352834 Free PMC article.
-
Hox transcript antisense RNA knockdown inhibits osteosarcoma progression by regulating the phosphoinositide 3-kinase/AKT pathway through the microRNA miR-6888-3p/spleen tyrosine kinase axis.Bioengineered. 2022 Apr;13(4):9397-9410. doi: 10.1080/21655979.2022.2059614. Bioengineered. 2022. PMID: 35435107 Free PMC article.
References
-
- Biermann JS, Adkins DR, Agulnik M, et al. Bone cancer. J Natl Compr Canc Netw. 2013;11(6):688–723. - PubMed
-
- National Institutes of Health SEER; Cancer Stat Facts: Bone and Joint Cancer. [Accessed November 2, 2017]. Available from: https://seer.cancer.gov/statfacts/html/bones.html.
-
- Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome – the French pediatric experience. Cancer. 2005;104(5):1100–1109. - PubMed
-
- Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21(10):2011–2018. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources